The Mechanism and Utility of CPI-613 for the Treatment of Hematologic Malignancies

Video

Timothy S. Pardee, MD, from Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.

Clinical Pearls

Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.

  • A phase I study is analyzing the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies
  • CPI-613 attacks cancer cells by hitting the mitochondria, which alters the ability of the cells to make the building blocks of the next cancer cell
  • In the trial, 40% of the 21 evaluable and heavily-pretreated patients responded
  • There was some evidence of acute renal failure, nausea, and diarrhea associated with the trial, though no myelosuppression was observed
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Exploring the Link Between HPV Infection and Head and Neck Cancers

Exploring the Link Between HPV Infection and Head and Neck Cancers

April 25th 2024
Article

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.

Read More

Legislative Changes and Their Impact on Community Oncology Care

Legislative Changes and Their Impact on Community Oncology Care

April 24th 2024
Article

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

Read More

Investigating Pregnancy and Transplant Match Issues

Investigating Pregnancy and Transplant Match Issues

April 24th 2024
Article

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

Read More

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More

Improving Identification Within Asian American Subgroups With Ovarian Cancer

Improving Identification Within Asian American Subgroups With Ovarian Cancer

April 12th 2024
Article

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

Read More

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

April 11th 2024
Article

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

Read More